IMMATURE AND EXHAUSTED NK/T-CELL PROFILE PRECEDES MOLECULAR RELAPSE AND PREDICTS TREATMENT-FREE REMISSION FAILURE: DATA FROM THE DES-CML TRIAL

In Chronic Myeloid Leukemia (CML), only 50% of patients achieving deep molecular response (DMR) maintain long-term treatment-free remission (TFR) after tyrosine kinase inhibitor (TKI) discontinuation. Biomarkers predicting molecular relapse remain undefined. We hypothesized that distinct antitumoral immune signatures mediated by Natural Killer (NK) and T cells drive TFR outcomes. NK and T-cell imm…